Welcome to Grünenthal. This site uses cookies. Read our policy.

Accept Cookies

Patient Voice
in Gout


Why a patient survey in gout?

Gout is the most common form of inflammatory arthritis in Europe, yet awareness of it is relatively low. Existing data indicate that gout has a significant impact on patients’ lives. Thus, Grünenthal, in collaboration with several patient and clinical experts, has designed this survey to give people with gout a voice.

Who can participate?

Every person above 18 years of age with a diagnosis of gout from the following European countries can take part: Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Malta, Netherlands, Norway, Portugal, Spain, Sweden and Switzerland. We plan that at least 1000 gout patients will complete this survey.

What will be asked?

This is an online survey which takes about 15 minutes to collect information about the patient’s disease story, the patient’s (and the general public’s) knowledge about gout, the current status of their gout and the impact of the disease on their life.

When will the survey take place?

The survey will be open from mid June 2018 until the end of September 2018. Results of the survey will be shared and communicated in November 2018.

Join the survey

If you have any questions, please contact patientvoicegout@hallandpartners.com.

The survey has been initiated by the pharmaceutical company Grünenthal in collaboration with Neil Betteridge Associates and Hall & Partners. The design and content of the survey has been developed together with several patient and clinical experts.


The initiative is supported by the following European patient organisations: